Published on 23/12/2025
Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines
Introduction to GPP: Why Ethical Publication Matters
Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).
These guidelines aim to promote transparency, responsible authorship, and ethical sponsor engagement in the publication of clinical trial data. GPP applies to pharmaceutical companies, contract research organizations (CROs), academic collaborators, and medical writers involved in the publication planning and dissemination process.
Core Principles of GPP3
GPP3 outlines the ethical standards and operational expectations for preparing and publishing trial-related manuscripts. Core principles include:
- Transparency: Disclose sponsor involvement, funding sources, and data access rights clearly.
- Accountability: Ensure all listed authors meet the ICMJE authorship criteria.
- Accuracy: Report trial results honestly, without bias, spin, or data manipulation.
- Timeliness: Publish results in a timely manner consistent with regulatory disclosure timelines.
- Respect for contributors: Acknowledge the roles of statisticians, writers, and investigators.
These standards align with ICMJE’s Uniform Requirements and complement regulatory requirements from FDA, EMA,
Authorship Ethics: Avoiding Misconduct
One of the most critical elements in ethical publishing is defining who qualifies as an author. According to both GPP and ICMJE guidelines, authors must meet all of the following criteria:
- Substantial contribution to study design, data analysis, or interpretation
- Drafting or revising the article critically for intellectual content
- Approval of the final version for publication
- Accountability for the accuracy and integrity of the published content
GPP3 strongly discourages ghostwriting—where individuals contribute without acknowledgment—or guest authorship—where individuals are credited without meaningful contribution. Both practices are considered publication misconduct.
Managing Sponsor Involvement and Independence
Sponsors often fund and manage trials, but their role in publication must be disclosed and regulated. Ethical sponsor practices include:
- Allowing authors full access to data or summary-level analyses
- Refraining from controlling the publication’s message or conclusions
- Disclosing conflicts of interest (COIs) related to employment, funding, or stock ownership
- Ensuring transparency about editorial assistance from medical writers
Example: In a multi-site trial on a novel anticoagulant, the sponsor may support writing through an external medical communication agency. However, all authors should approve the content, and the writer’s name and funding source must be disclosed.
Publication Planning and Documentation
Ethical publication also involves organized planning. GPP3 recommends sponsors and authors collaboratively develop a publication plan that includes:
- A publication timeline linked to trial milestones (e.g., database lock, CSR finalization)
- A list of planned abstracts, posters, and manuscripts
- Defined roles and responsibilities for each author and contributor
- A process for conflict resolution and content approval
Publication plans help avoid publication bias by documenting the intent to publish all prespecified outcomes, regardless of result significance. Many sponsors now maintain internal SOPs to govern these workflows.
External Guidelines Complementing GPP
GPP guidelines work in tandem with several other international frameworks:
- EU CTR: Requires summary results and layperson summaries within 12 months of trial completion
- FDAAA 801: Mandates results reporting on ClinicalTrials.gov
- ICMJE: Sets criteria for authorship and trial registration
- WHO ICTRP: Advocates for global result disclosure standards
GPP-compliant sponsors should ensure their practices do not contradict these overlapping obligations.
Role of Medical Writers and Review Committees
Medical writers play an integral role in transforming complex trial data into clear, accurate, and ethical publications. GPP encourages acknowledgment of their work and insists on:
- Documentation of writing contributions in the manuscript or submission form
- Verification that writers had no role in data manipulation or outcome shaping
- Confirmation that writers received direction from authors, not solely from the sponsor
Meanwhile, publication review committees (PRCs) at many organizations ensure that all manuscripts meet internal quality standards and GPP principles before journal submission.
Common Violations and Their Consequences
GPP violations can lead to severe reputational and regulatory consequences. Common violations include:
- Failing to disclose sponsor involvement
- Publishing only favorable outcomes (publication bias)
- Suppressing trial data or delaying negative result publication
- Adding honorary or ghost authors
- Not declaring writer contributions or financial support
Example: In a 2020 audit of 75 industry-sponsored trials published in top journals, over 20% failed to disclose medical writing support—despite involvement. Journals like The Lancet and BMJ have since tightened disclosure policies.
Conclusion: Making GPP a Standard Practice
The GPP guidelines represent a foundational framework for ethical trial result publication. Implementing GPP practices not only ensures compliance but fosters trust among peers, regulators, patients, and the public. Sponsors, CROs, and academic institutions should integrate GPP into their publication SOPs, training, and governance systems.
As clinical trial disclosure becomes increasingly regulated, ethical publication isn’t just a best practice—it’s a moral, scientific, and legal imperative. Upholding GPP principles safeguards the value of medical research and protects the patients whose participation makes it possible.